Starton Therapeutics Inc CEO Pedro Lichtinger wants patients using cancer-fighting drug Revlimid to have better and longer lives.
Celgene created the blood cancer treatment, also known as lenalidomide, for sufferers of multiple myeloma, mantle cell lymphoma, and lymphoma to treat and boost the body’s immune system. The drug became the standard of care in multiple myeloma, the most common blood cancer in the US. Celgene was acquired by Bristol Myers Squibb.
But unfortunately for patients, the drug can produce nasty side effects, such as neutropenia, diarrhea, and kidney damage. And many patients simply can’t tolerate it at all, forcing them to turn to less-effective drugs that carry fewer side effects and the likelihood of poorer outcomes.
Another big concern with orally administered Revlimid is dosage. At high levels of concentration in the patient’s blood, unwanted side effects typically occur. When concentrations of the drug are low, it may be less effective, giving …